In parallel with their peripheral induction, the cerebral

expression of IFN-γ and IL-6, was synergistically enhanced by FK565 + LPS and MDP + LPS, while the increase of cerebral IL-1β and TNF-α mRNA expression was rather additive. Thus, the effects of NOD agonists to prime the production of proinflammatory cytokines in response to LPS exhibit different patterns of interaction in the periphery and brain, depending on the compounds investigated. While this interaction is of a primarily see more synergistic nature in the periphery, the interaction in the brain can either be of an additive or synergistic manner. This different pattern of interaction is also reflected by different time

courses of cytokine induction in the periphery and brain. While the PRR-evoked increase in plasma cytokines had largely waned 1 day post-treatment, the cerebral expression of IL-1β and TNF-α mRNA was still elevated. The most striking difference was seen with IL-6, the plasma levels of which remained elevated 1 day after treatment with LPS, MDP + LPS and FK565 + LPS, whereas the cerebral expression of IL-6 mRNA was reduced by these treatments, as previously described for LPS (Andre et al., 2008 and Bay-Richter et al., 2011). Collectively, our findings suggest Anti-diabetic Compound Library that the sickness response to combined NLR and TLR agonism is initiated by immune stimulation which in turn activates secondary mechanisms that drive illness. Kynurenine may play such a role, given that its plasma level was significantly more enhanced by the combination treatments than by LPS alone and remained significantly elevated 1 day post-treatment. In line with this contention, blockade of IDO decreases kynurenine levels and abrogates LPS-induced depression-like behavior without changing brain cytokine expression (O’connor et al., 2009). Proinflammatory cytokines, particularly IFN-γ and TNF-α, activate IDO and lead to the conversion of tryptophan to kynurenine which in rodents

elicits depression-like behavior (O’connor et al., 2009). The increase DOK2 in plasma tryptophan seen here contrasts with a decrease of tryptophan seen in other studies (O’connor et al., 2009) but may be related to the TST employed 30 min before blood sampling, given that stress can increase peripheral tryptophan levels in rodents, but the underlying mechanisms are not understood (Dunn, 1988 and Malyszko et al., 1995). It is, however, emerging that not tryptophan depletion but kynurenine production contributes to the behavioral effects of immune activation (O’connor et al., 2009). Although peripheral tryptophan may decrease in response to LPS, the availability of tryptophan to the brain remains unchanged and brain tryptophan may even increase (O’connor et al., 2009).